Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ other cardiovascular — Sales to Customers

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Organon logo
OGNOther Cardiovascular — Revenue
$28M-6.7%
ITG
ITGRCardio & Vascular — Total sales
$261.73M+1.1%
Medtronic logo
MDTCardiovascular — Net Sales
$3.8B+13.8%
Boston Scientific logo
BSXCardiovascular — Net Sales
$3.5B+13.5%
Boston Scientific logo
BSXCardiovascular — Net sales of reportable segments
$3.5B+10.9%
Lantheus Holdings logo
LNTHCardiology — Revenue
$84.63M+6.8%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-K, filed February 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's other cardiovascular — sales to customers.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's other cardiovascular — sales to customers?
Johnson & Johnson (JNJ) reported other cardiovascular — sales to customers of $99.25M in Q4 2025.
How has Johnson & Johnson's other cardiovascular — sales to customers changed year-over-year?
Johnson & Johnson's other cardiovascular — sales to customers increased by 4.5% year-over-year, from $95M to $99.25M.
What is the long-term trend for Johnson & Johnson's other cardiovascular — sales to customers?
Over 3 years (2022 to 2025), Johnson & Johnson's other cardiovascular — sales to customers has grown at a 6.1% compound annual growth rate (CAGR), from $332M to $397M.
What does other cardiovascular — sales to customers mean?
This metric represents the total revenue generated from the sale of cardiovascular medical devices and related products that fall outside of the company's primary or core cardiovascular product categories. It serves as a measure of the market demand and commercial performance for niche or specialized cardiovascular therapeutic solutions. Tracking this revenue helps investors understand the contribution of secondary cardiovascular portfolios to the overall medical technology business segment.